Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
العنوان: | Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study |
---|---|
المؤلفون: | Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski |
المصدر: | Blood. 140:9995-9997 |
بيانات النشر: | American Society of Hematology, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | Immunology, Cell Biology, Hematology, Biochemistry |
تدمد: | 1528-0020 0006-4971 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::368da8e5a1eb1891530e35e672f38c44Test https://doi.org/10.1182/blood-2022-163092Test |
رقم الانضمام: | edsair.doi...........368da8e5a1eb1891530e35e672f38c44 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 15280020 00064971 |
---|